Ramsey, Haley E.
Oganesian, Aram
Gorska, Agnieszka E.
Fuller, Londa
Arrate, Maria
Boyd, Kelli
Keer, Harold
Azab, Mohammad
Savona, Michael R.
Funding for this research was provided by:
Astex Pharmaceuticals
Biff Rittenberg Foundation
Article History
First Online: 28 March 2020
Compliance with Ethical Standards
:
: This study, including open-access publication costs, were supported by Astex Pharmaceuticals and the Biff Rittenberg Foundation. In addition, the Vanderbilt-Ingram Cancer Center (VICC) Hematopoietic Malignancies Tissue Repository, the Vanderbilt University Medical Center Translational Pathology Shared Resource, and other VICC shared Core Services were critical in completion of this work. This project has been funded in part with Federal funds from the National Cancer Institute. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. The Vanderbilt-Ingram Cancer Center is supported by an NIH P30 CA068485-19. The REDCap database tool is supported by Grant UL1 TR000445 from NCATS/NIH. MS is a Leukemia and Lymphoma Society Clinical Scholar.
: Aram Oganesian, Harold Keer, and Mohammad Azab are employees of Astex Pharmaceuticals. Michael R. Savona has equity ownership in Karyopharm; receives research funding from Astex, Incyte, Millennium, Sunesis, and TG Therapeutics; serves on consultancy/advisory board/monitoring committees for Abbvie, BMS, Celgene, Incyte, Karyopharm, Millennium, Sierra Oncology, Ryvu, and TG Therapeutics; and has patents and royalties with Boehringer-Ingelheim. Haley E. Ramsey, Agnieszka E. Gorska, Londa Fuller, Maria Arrate, and Kelli Boyd declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.